X

Trial Profile

GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acimtamig (Primary)
Indications Hodgkin's disease
Focus Proof of concept; Therapeutic Use
Acronyms GHSG-AFM13

Most Recent Events

01 Aug 2022 Final Results published in the Leukemia and Lymphoma
08 Dec 2020 Protocol was amended for all further patients received 7 mg per kg per week, with 1 mg per kg loading dose and 6 mg per kg as continuous infusion for 5 days/ week thereafter (Arm C).
08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com